1,062 results on '"Parekh, Samir"'
Search Results
52. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity
53. Proteasome Inhibitors with a Focus on Bortezomib
54. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma
55. Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
56. Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
57. Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
58. Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
59. MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy
60. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
61. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
62. SOX11 augments BCR signaling to drive MCL-like tumor development
63. Regression of smoldering myeloma with treatment of Gaucher disease
64. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
65. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
66. P-381 Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients
67. P-043 Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): early results from an IIT
68. P-379 Variable humoral and cellular responses to SARS-CoV-2 bivalent booster vaccination in patients with multiple myeloma
69. Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab
70. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
71. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
72. Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
73. Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting
74. Data from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
75. Supplementary Table S1 from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
76. Supplementary Figures from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
77. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL
78. Supplementary Figure 2 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
79. Data from Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
80. Supplementary Figure 6 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
81. Supplementary Data from SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma
82. Supplementary Figure 3 from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
83. Supplementary Figure Legend from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
84. Supplementary Figure 1 from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
85. Supplementary Figure 2 from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
86. Supplementary Data from Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
87. Supplementary Figure 5 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
88. Supplementary Figure 3 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
89. Supplementary Figure 1 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
90. Supplementary Figure 7 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
91. Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
92. Supplementary Figure 4 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
93. Supplementary Tables S1-S4 from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma
94. Supplementary Figures S1-S11 from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma
95. Data from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma
96. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone–treated donors in neutropenic patients with infection
97. Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings
98. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma
99. Dupilumab in Multiple Myeloma: A Case Series
100. Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.